Winslow R S, Stillner V, Coons D J, Robison M W
Am J Psychiatry. 1986 Jun;143(6):706-10. doi: 10.1176/ajp.143.6.706.
The authors performed a prospective double-blind study of 39 inpatients beginning high-potency neuroleptics. Patients were randomly assigned to a 7-day course of benztropine or placebo in addition to a neuroleptic. Of 17 patients receiving placebo, eight (47%) suffered an acute dystonic reaction; of 22 patients receiving benztropine, none suffered this reaction--a highly significant difference. The authors also found minimal anticholinergic toxicity attributable to the addition of benztropine to the neuroleptic regimen. These results suggest that an initial 7-day prophylaxis with benztropine is a high-benefit, low-risk adjunctive treatment to neuroleptic therapy.
作者对39名开始使用高效能抗精神病药物的住院患者进行了一项前瞻性双盲研究。患者除服用抗精神病药物外,还被随机分配接受为期7天的苯海索或安慰剂治疗。在17名接受安慰剂治疗的患者中,有8名(47%)发生了急性肌张力障碍反应;在22名接受苯海索治疗的患者中,无人发生这种反应——差异极具显著性。作者还发现,在抗精神病药物治疗方案中添加苯海索所致的抗胆碱能毒性极小。这些结果表明,苯海索初始7天预防治疗是抗精神病药物治疗的一种高效益、低风险的辅助治疗方法。